Intensive monitoring of new drugs based on first prescription signals from pharmacists: A pilot study

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 6, 2003, Pages 475-481

  van Grootheest, A C ^a   Groote, J K ^b   de Jong van den Berg, L T W ^b  

^a NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

^b GUIDE   (Netherlands)

Author keywords

Adverse drug reactions; First delivery signal; Intensive monitoring; Lareb; Pharmacists

Indexed keywords

NEW DRUG; ROFECOXIB;

ANAMNESIS; ARTICLE; ATTITUDE; COMPUTER SYSTEM; CONTROLLED STUDY; COOPERATION; DOSE RESPONSE; DRUG INDICATION; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEALTH CARE DELIVERY; HUMAN; OSTEOARTHRITIS; PHARMACIST; PHARMACY; PILOT STUDY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CYCLOOXYGENASE INHIBITORS; HUMANS; LACTONES; PHARMACISTS; PILOT PROJECTS; PRESCRIPTIONS, DRUG; SULFONES;

EID: 0042413917     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.815     Document Type: Article

References (16)

1. Porta M, Hartzema AG, Tilson HH. The contribution of epidemiology to the study of drug uses and effects. In Pharmacoepidemiology-An Introduction (3rd edn), Hartzema AG, Porta M, Tildon HH (eds). Harvey Whitney Books Company: Cincinnati, 1998; 1-28.
2. Olsson S. National Pharmacovigilance Systems, Country Profiles and Overview (2nd edn). Uppsala: WHO Uppsala Monitoring Centre, 1999.
3. Weber JCP. Epidemiology of adverse reactions to non-steroidal antiinflammatory drugs. Adv in Inflam Res. 1984; 6: 1-7.
4. Haramburu F, Bégaud B, Moride Y. Temporal trends in spontaneous reporting of unlabelled adverse drug reactions. Br J Clin Pharmacol 1997; 44: 299-301.
5. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports, the Weber Effect revisited. Drug Safe 2001; 24: 233-237.
6. Coulter DM. The New Zealand intensive medicines monitoring programme. Pharmacoepidemiol Drug Safe 1998, 7: 79-90.
7. Mann RD, Wilton LV, Pearce GL, Mackay FJ, Dunn NR. Prescription-event monitoring in 1996-a method of noninterventional observational cohort pharmacovigilance. Pharmacoepidemiol Drug Safe 1997; 6: S5-S11.
8. Coulter DM. The New Zealand intensive medicines monitoring programme in pro-active safety surveillance. Pharmacoepidemiol Drug Safe 2000; 9: 173-180.
9. Mann RD. Prescription-event monitoring-recent progress and future horizons. Br J Clin Pharmacol 1998; 46: 195-201.
10. Mackay FJ. Post-marketing studies. The work of the drug safety research unit. Drug Safety 1998; 19: 143-153.
11. Inman H. Postmarketing surveillance of adverse drug reactions in general practice II: prescription event monitoring at the University of Southampton. BMJ 1981; 282: 1216-1217.
12. Grootheest AC van, Puijenbroek EP van, Jong-van den Berg LTW de. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Safe 2002; 11: 205-210.
13. Eland IA, Belton KJ, van Grootheest AC, et al. Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol 1999; 48: 623-627.
14. Grasela TH. Hospital drug surveillance networks: ad hoc pharmacoepidemiologic data collection methods. In Pharmacoepidemiology-An Introduction (3rd edn), Hartzema AG, Porta M, Tildon HH (eds). Harvey Whitney Books Company: Cincinnati, 1998; 389-404.
15. Puijenbroek EP. Quantitative Signal Detection in Pharmacovigilance. Utrecht, 2001 (thesis).
16. Meyboom RHB, Egberts ACG, Edwards IR, Hekster YA, Koning FHP de, Gribnau FWJ. Principles of signal detection in pharmacovigilance. Drug Safe 1997; 16: 155-165.